IR
BIO icon

Invictus RG’s Bio-Rad Laboratories Class A BIO Stock Holding History

Invictus RG’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-843
Closed -$264K – 23
2018
Q3 		$264K Sell
843
-86
-9% -$26.7K 0.2% 158
2018
Q2 		$268K Sell
929
-63
-6% -$17.4K 0.23% 145
2018
Q1 		$248K Buy
+992
New +$253K 0.17% 212
2017
Q3 		– Sell
-1,774
Closed -$401K – 506
2017
Q2 		$401K Buy
+1,774
New +$387K 0.29% 113
2016
Q1 		– Sell
-36
Closed -$5K – 597
2015
Q4 		$5K Buy
+36
New +$4.99K ﹤0.01% 553

Other funds holding BIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Invictus RG's BIO Position: Q4 2018 in Review

Invictus RG sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2018, closing a stake of 843 shares — an estimated $264K sold.

Invictus RG first reported a position in BIO in Q4 2015 and held it in 5 quarters. The position peaked at $401K in Q2 2017. 329 funds tracked by Wall St. Rank hold BIO as of Q4 2018.

  • Invictus RG reported no remaining Bio-Rad Laboratories Class A position as of Q4 2018 after selling out during the quarter.
  • Invictus RG sold 843 Bio-Rad Laboratories Class A shares in Q4 2018, an estimated $264K.
  • Invictus RG first reported a position in Bio-Rad Laboratories Class A in Q4 2015 and held it in 5 quarters.
  • Invictus RG's Bio-Rad Laboratories Class A position peaked at $401K in Q2 2017.
  • 329 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2018.

Based on Invictus RG's 13F filing for Q4 2018, filed 13 Feb 2019.